Nektar Therapeutics dips after announcing equity offering

Nektar Therapeutics

30/06/2025 21:49

** Shares of Nektar Therapeutics NKTR.O down 1.9% to $25.36 after potential equity raise news

    ** San Francisco-based firm launches offering of stock and pre-funded warrants

    ** It intends to use net proceeds for R&D, clinical development and manufacturing costs to support advancement of its drug candidates, along with other general purposes

** Jefferies and Piper Sandler are jt bookrunners for offering

    ** Last Tues, NKTR shares soared 156% to close at $24.45 after its eczema drug met main goal in mid-stage study

    ** With ~12.4 mln shares outstanding, co has roughly $320 mln market cap

    ** NKTR shares closed up 0.3% at $25.84 in Monday's regular session

    ** Earlier this month, co effected 1-for-15 reverse stock split

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))